Adial Pharmaceuticals, Inc. Equity Ownership Percentage Excluding Consolidated Entity And Equity Method Investee
Adial Pharmaceuticals, Inc. (ADIL) had Equity Ownership Percentage Excluding Consolidated Entity And Equity Method Investee of 15.00% as of 2023-06-30, per its 10-K filed 2025-03-04.
Financial Statements › Notes › Investments
us-gaap:EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee · last filed 2025-03-04
- 2023-06-30: Equity Ownership Percentage Excluding Consolidated Entity And Equity Method Investee 15.00%; Equity Ownership Percentage Excluding Consolidated Entity And Equity Method Investee as first filed 19.90%.
| Period end | Equity Ownership Percentage Excluding Consolidated Entity And Equity Method Investee | Equity Ownership Percentage Excluding Consolidated Entity And Equity Method Investee as first filed |
|---|---|---|
| 2023-06-30 | 15.00% 10-K · filed 2025-03-04 | 19.90% 10-Q · filed 2023-08-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |